BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The global demand for highly potent drugs is growing rapidly\,
  with the market projected to reach $46.9B by 2030\, driven by innovation
 s in drug delivery technologies\, regulatory advancements\, and the risin
 g need for personalized treatments. The oncology sector has been a key wi
 tness to this\, experiencing substantial growth due to the increasing ado
 ption of small molecules\, conjugates\, and other targeted therapies.\n\n
 At the forefront of it all\, we're thrilled to announce that the 14th Hig
 hly Potent Drug Manufacturing Summit is back in August 2025\, offering in
 -depth case studies on the latest innovations in developing cytotoxic com
 pounds\, strengthening process collaborations\, and safely scaling up man
 ufacturing.\n\nAs a free-to-attend* event for drug developers this year i
 n Boston\, you'll experience a completely revamped agenda\, designed to m
 eet the industry's evolving needs of 90+ Vice Presidents\, Directors\, an
 d Heads of CMC\, Tech Operations\, Process Chemistry\, Drug Substance and
  Product\, EHS\, and Industrial Hygiene.\n\nWhether you'd like to secure 
 the best CDMO\, optimize upstream development\, or create a work environm
 ent conducive to occupational safety\, this is the place to be!\n\nHear f
 rom some of our most renowned speakers and network with your forward-thin
 king peers from the likes of Pfizer\, Bristol Myers Squibb\, Johnson and 
 Johnson\, Biogen\, Teva Pharmaceuticals\, Relay Therapeutics\, and more.\
 n\nURLs:Tickets: https://go.evvnt.com/2958544-2?pid=185Brochure: https://
 go.evvnt.com/2958544-3?pid=185LinkedIn: https://go.evvnt.com/2958544-4?pi
 d=185\n\nTime: 8:00 AM - 2:45 PM\n\nPrices:Drug Developer and Academic Pr
 icing: USD 0.50\,Solution Providers: USD 3699.00\n\nSpeakers: Thomas Fent
 on\, Senior Specialist\, EHS\, Alkermes\, Omid ZadakBar\, Senior Manager\
 , Global EHS Design Engineering\, Amgen\, Linda Jackowiak\, Associate Dir
 ector\, EHS\, Chemical Safety and Industrial Hygiene\, AstraZeneca\, Thom
 as Adam\, Head\, Global Quality Assurance\, Chemical API\, Bayer\, Suzie 
 Opalka\, Associate Director\, Chemical Process Development\, Biogen\, Tae
  Correia\, Associate Scientist\, Technical Development\, Biogen\, Ronald 
 Amoling\, Associate Director\, EHS\, Bristol Myers Squibb\, Jarrod Longco
 r\, Chief Operating Officer\, Cellectar Biosciences\, Bernard Shamsai\, E
 xecutive Director\, Process Development\, Gilead Sciences\, Rupesh Nanjun
 da\, Associate Director\, Biologics Drug Product Development\, Johnson an
 d Johnson\, David Cragin\, Senior Director\, Product Science\, EHS and Su
 stainability\, Teva Pharmaceuticals\, Talia Planas-Fontanez\, Senior Occu
 pational Toxicologist\, EHS and Sustainability\, Teva Pharmaceuticals\, N
 aiffer Romero\, Principal Scientist\, Scientific Affairs\, US Pharmacopei
 a\, Mark Witcher\, Subject Matter Expert\, Biopharma Operations\, Indepen
 dent\, Srinath Thirumalairajan\, Director\, Process Engineering\, Small M
 olecules\, Pfizer\, Surendra Singh\, Vice President\, Drug Substance Deve
 lopment and Manufacturing\, CMC\, Relay Therapeutics\n
DTEND:20250814T144500
DTSTAMP:20260512T220339Z
DTSTART:20250813T080000
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, Massach
 usetts\, 02116\,
SEQUENCE:0
SUMMARY:The global demand for highly potent drugs is growing rapidly\, wit
 h the market projected to reach $46.9B by 2030\, driven by innovations in
  drug deli...
UID:1803b5d8-f4d4-44e0-a6f1-193b7e7960db
END:VEVENT
END:VCALENDAR